Symbols

PYPD

PolyPid·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Consensus Rating "Strong Buy"

Bearish Engulfing

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PYPD

Polypid Ltd.

A biopharmaceutical company developing and commercializing extended-release, locally administered therapies

Industry

Pharmaceutical

Established Date

02/28/2008

Listing Date

06/26/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.polypid.com

Security Type

Common stock

Office address

18 Hasivim Street Petach Tikva 495376 Israel

Business

Introduction

PolyPid Ltd., incorporated under the laws of Israel, commenced operations on February 28, 2008. The Company is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, topically administered and sustained-release therapies using its proprietary PLEX technology. The Company's product candidates are designed to achieve novel therapeutic effects by combining PLEX technology with FDA-approved drugs or innovative drugs to meet significant unmet medical needs.

Company Financials

EPS

PYPD has released its 2025 Q4 earnings. EPS was reported at -0.41, versus the expected -0.33, missing expectations. The chart below visualizes how PYPD has performed over recent quarters, highlighting trends in earnings surprises.